Alpaslan KABAN, Samet TOPUZ, Hamdullah SÖZEN, Yavuz SALİHOGLU

109104

İLERİ EVRE YÜKSEK GRADE ENDOMETRİUM KANSERLİ HASTALARDA SAĞKALIM SONUÇLARI

ÖzAmaç: İleri evre (FIGO III-IV) yüksek gradeli endometrium kanserli hastaların genel sağkalım ve hastalıksız sağkalımlarını değerlendirmek
Anahtar Kelimeler:

seröz, berrak hücreli, karsinosarkom, mikst, grade 3 endometrioid ve undiferansiye

SURVIVAL RESULTS OF PATIENTS WITH HIGH-GRADE AND ADVANCED-STAGE ENDOMETRIAL CANCER

Purpose: To evaluate the overall survival and disease-free survival in patients with advanced-stage(FIGO III-IV) and high-grade endometriumcancerPatients and Methods: Patients with operated due to endometrial cancer between 2003-2014 and detected FIGO-stage III-IV serous, clearcell,carcinosarcoma, mixed, grade 3 endometrioid, and undifferentiated histological types according to postoperative pathology reportwere selected for the study. Overall survival and disease-free survival times were calculated by Kaplan-Meier survival analysis for each histologictype.Results: A total of 85 patients with a median-age of 65(37-86) were included in the study. Of them, 56(65.9%) were stage-III and 29(34.1%)were stage-IV. The most common histological-type was carcinosarcoma(25.9%, n=22) followed by mixed(22.4%,n=19), serous(17.6%,n=18),grade 3 endometrioid(17.6% cell (8.2%,n=7) and undifferentiated(4.7%,n=4). During a mean follow-up of 37.1 months(1-148), 63 patients(74.1%) had recurrence and 60 patients(70.6%) died. The overall survival rate was 29.4%. The highest survival rates were mixed type andgrade 3 endometrioid types(42.1% and 40%) followed by serous(33.3%) and clear-cell(28.6%) and carcinosarcoma(13.6%) and no survival inundifferentiated type. Median disease-free survival and overall survival were 24 and 49 months for serous type, 28 and 34 months for grade3 endometrioid type, 15 and 27 months for mixed type, 9 and 18 months for clear cell, 10 and 21 months for carcinosarcoma, 3 and 4 monthsfor the undifferentiated typeConclusion: The median disease-free and overall survival of patients were 12 and 28 months, respectively, according to the data of thisstudy. 74.1% of the patients relapse. The worst prognosis is with undifferentiated types. The prognosis for Grade-3 endometrioid and mixedtypes seems to be relatively better.
Keywords:

serous, clear cell, carcinosarcoma, mixed, grade 3 endometrioid and undifferentiated,

PDF

___

  • 1. Gottwald L, Pluta P, Piekarski J, Spych M, Hendzel K, Topczewska-Tylinska K, et al. Long-term survival of endometrioid endometrial cancer patients. Arch Med Sci. 2010;6(6):937–44.
  • 2. Reynaers EAEM, Ezendam NPM, Pijnenborg JMA. Comparable outcome between endometrioid and nonendometrioid tumors in patients with early-stage highgrade endometrial cancer. J Surg Oncol. 2015;111(6):790– 4.
  • 3. Oliva E, Soslow RA. High-Grade Endometrial Carcinomas. Vol. 4, Surgical Pathology Clinics. 2011. p. 199–241.
  • 4. Soslow RA. High-grade endometrial carcinomas - strategies for typing. Vol. 62, Histopathology. 2013. p. 89–110.
  • 5. Amant F, Moerman P, Neven P, Timmerman D, Van Limbergen E, Vergote I. Endometrial cancer. Lancet (London, England). 2005;366(9484):491–505.
  • 6. Sorosky JI. Endometrial cancer. Obstet Gynecol. 2012;120(2 Pt 1):383–97.
  • 7. Morice P, Leary A, Creutzberg C, Abu-Rustum N, Darai E. Endometrial cancer. In: The Lancet. 2016. p. 1094–108.
  • 8. Lee NK. Adjuvant treatment of advanced-stage endometrial cancer. Clin Obstet Gynecol. 2011;54(2):256–65.
  • 9. Tangjitgamol S, See HT, Kavanagh J. Adjuvant chemotherapy for endometrial cancer. Int J Gynecol Cancer. 2011;21(5):885–95.
  • 10. Cantrell LA, Blank S V., Duska LR. Uterine carcinosarcoma: A review of the literature. Vol. 137, Gynecologic Oncology. 2015. p. 581–8.
  • 11. Ferguson SE, Tornos C, Hummer A, Barakat RR, Soslow RA. Prognostic features of surgical stage I uterine carcinosarcoma. Am J Surg Pathol. 2007;31(11):1653–61.
  • 12. Gokce ZK, Turan T, Karalok A, Tasci T, Ureyen I, Ozkaya E, et al. Clinical outcomes of uterine carcinosarcoma: results of 94 patients. Int J Gynecol Cancer. 2015;25(2):279– 87.
  • 13. Vaidya AP, Horowitz NS, Oliva E, Halpern EF, Duska LR. Uterine malignant mixed mullerian tumors should not be included in studies of endometrial carcinoma. Gynecol Oncol. 2006;103(2):684–7.
  • 14. Roelofsen T, van Ham MAPC, Wiersma van Tilburg JM, Zomer SF, Bol M, Massuger LFAG, et al. Pure Compared With Mixed Serous Endometrial Carcinoma. Obstet Gynecol. 2012;120(6):1371–81.
  • 15. Espinosa I, D’Angelo E, Palacios J, Prat J. Mixed and ambiguous endometrial carcinomas. Am J Surg Pathol. 2016;40(7):972–81.
  • 16. Moore KN, Fader AN. Uterine papillary serous carcinoma. Clin Obstet Gynecol. 2011;54(2):278–91.
  • 17. Ayeni TA, Bakkum-Gamez JN, Mariani A, McGree ME, Weaver AL, Haddock MG, et al. Comparative outcomes assessment of uterine grade 3 endometrioid, serous, and clear cell carcinomas. Gynecol Oncol. 2013;129(3):478– 85.
  • 18. Felix AS, Stone RA, Bowser R, Chivukula M, Edwards RP, Weissfeld JL, et al. Comparison of survival outcomes between patients with malignant mixed mullerian tumors and high-grade endometrioid, clear cell, and papillary serous endometrial cancers. Int J Gynecol Cancer. 2011;21(5):877–84.
  • 19. Hamilton C, Cheung M, Osann K, Chen L, Teng N, Longacre T, et al. Uterine papillary serous and clear cell carcinomas predict for poorer survival compared to grade 3 endometrioid corpus cancers. Br J Cancer. 2006;94(5):642–6.
  • 20. Greggi S, Mangili G, Scaffa C, Scala F, Losito S, Iodice F, et al. Uterine papillary serous, clear cell, and poorly differentiated endometrioid carcinomas: a comparative study. Int J Gynecol Cancer. 2011;21(4):661–7.
  • 21. Alkushi A, Köbel M, Kalloger SE, Gilks CB. High-Grade Endometrial Carcinoma: Serous and Grade 3 Endometrioid Carcinomas Have Different Immunophenotypes and Outcomes. Int J Gynecol Pathol. 2010;29(4):343–50.
Türk Jinekolojik Onkoloji Dergisi-Cover
  • ISSN: 2148-5372
  • Başlangıç: 2014
  • Yayıncı: Türk Jinekolojik Onkoloji Derneği
Arşiv
Sayıdaki Diğer Makaleler

İLERİ EVRE YÜKSEK GRADE ENDOMETRİUM KANSERLİ HASTALARDA SAĞKALIM SONUÇLARI

Alpaslan KABAN, Samet TOPUZ, Hamdullah SÖZEN, Yavuz SALİHOGLU

HUMAN PAPİLLOMAVİRUS GENOTİPLERİNİN PYROSEQUENCİNG METODU İLE TESPİTİ

Serap ÖZEN, Mehmet ÇİMENTEPE, Buket ŞEFLEK, Mehmet Ali VARDAR, Derya GÜMÜRDÜLÜ, Fügen YARKIN

ASC-H (YÜKSEK DERECELİ LEZYONUN DIŞLANAMADIĞI ATİPİK HÜCRE) SİTOLOJİ SONUÇLARININ HİSTOLOJİK OLARAK DEĞERLENDİRİLMESİ

Aykut TUNCER, Ali AYHAN

SERVİKS KANSERİ YA DA SERVİKAL İNTRAEPİTHELİAL NEOPLAZİ SAPTANAN HASTALARIN HPV TEST SONUÇLARI

Aykut TUNCER, Ali AYHAN

EVRE I ENDOMETRİUM KANSERİNDE UYGULANAN RADYOTERAPİ ŞEKLİNİN UZUN DÖNEM YAN ETKİ SONUÇLARINA ETKİSİ: PELVİK EKSTERNAL RADYOTERAPİ VEYA VAGİNAL BRAKİTERAPİ?

Fatma SERT, Senem ALANYALI, Arif Bülent ARAS, Zeynep ÖZSARAN

GESTASYONEL TROFOBLASTİK HASTALIKLARA GÜNCEL YAKLAŞIM CONTEMPORARY

Kemal GÜNGÖRDÜK, Ceysu KOCAHAKİMOĞLU, Muzaffer SANCI, Özalp Sabit SİNAN, Varol GÜLSEREN, Dilek KARTAL